T-ALL diagnosis: cytogenetics, genomics and risk assessment

TL;DR

Genetic risk factors in TAL are still controversial due to the small number of patients and multiple independent genetic abnormalities. However, initial genetic analysis is crucial for identifying patients who can benefit from targeted therapies and building large cohorts for future risk stratification.

Transcript

tal genetics has been investigated for many years now and however the identification of genetic risk factors within tal is a much more controversial topic although we understand many of the genetic abnormalities that occur in tal both type a and type b abnormalities are as many researchers are now referring to them the identification of robust vali... Read More

Key Insights

• 🧑‍🏭 Genetic risk factors in TAL are still a controversial topic due to the small patient population and the presence of multiple independent genetic abnormalities.
• 🖐️ Initial genetic analysis plays a crucial role in identifying patients who can benefit from targeted therapies, such as those with able class fusion and kmt2a rearrangements.

Questions & Answers

Q: What are the challenges in identifying genetic risk factors in TAL?

Identifying genetic risk factors in TAL is challenging due to the small number of patients and the presence of multiple independent genetic abnormalities. This makes it difficult to gather large cohorts for robust statistical analysis.

Q: Why is initial genetic analysis important in TAL diagnosis?

Initial genetic analysis is crucial in TAL diagnosis for several reasons. Firstly, patients with able class fusion and kmt2a rearrangements can benefit from targeted therapies. Secondly, identifying key genetic lesions helps researchers build large cohorts for risk factor analysis. Lastly, it lays the foundation for future risk stratification efforts.

Q: What is the French oncogenetic classifier?

The French oncogenetic classifier is a risk stratification tool used in France for TAL patients. It assesses the mutational status of genes like notch one, f box seven, k-ras, n-ras, and p-10 to determine the risk profile. High-risk profile patients have an increased risk of relapse.

Q: Why did the oncogenetic classifier not validate in the UK?

The oncogenetic classifier did not validate in the UK, specifically in the UCal 2003 trial, due to the implementation of minimal residual disease (MRD)-directed therapy. The impact of MRD-directed therapy on the classifier's performance likely affected the results.

Key Insights:

• Genetic risk factors in TAL are still a controversial topic due to the small patient population and the presence of multiple independent genetic abnormalities.
• Initial genetic analysis plays a crucial role in identifying patients who can benefit from targeted therapies, such as those with able class fusion and kmt2a rearrangements.
• Building large cohorts of TAL patients through data sharing projects like Harmony is essential for identifying robust risk factors and improving risk stratification in the future.

Summary & Key Takeaways

• Despite understanding genetic abnormalities in TAL, identifying robust risk factors is challenging due to small patient numbers and multiple genetic abnormalities.

• Initial genetic analysis is vital for identifying patients with specific genetic abnormalities, such as able class fusion and kmt2a rearrangements, who can benefit from targeted therapies.

• The lack of widely accepted risk factors highlights the importance of large cohort studies and data sharing projects like Harmony to identify markers for future risk stratification.